Erythrocyte metabolism and renal anemia in hemodialyzed patients supplemented with L-carnitine

Alicja Slizien; Anna Owczarzak; Danuta Kunicka; Ewa Krol; Wieslawa Szydlowska; Boleslaw Rutkowski

Nephro-Urology Monthly

Current Issue All Issues In Press Accepted Manuscripts Search

Journal Information Boards and Committees Indexing and Listing Sources Journal Metrics Open Peer Review (OPR)Publication Ethics and Malpractice Statement Contact Us Support Reviewer and AE Registration Form

APC

Authors Guide Submit Manuscript

Erythrocyte metabolism and renal anemia in hemodialyzed patients supplemented with L-carnitine

Author(s):

Alicja Debska Slizien¹,

Anna Owczarzak^2,*,

Danuta Kunicka¹,

Ewa Krol¹,

Wieslawa Lysiak Szydlowska¹,

Boleslaw Rutkowski¹

1Department of Nephrology, Transplantology and Internal Medicine, Medical University of Gdansk, Poland

2Department of Clinical Nutrition, Institute of Internal Medicine, Medical University of Gdansk, annaow@amg.gda.pl, Poland

Nephro-Urology Monthly:Vol. 3, issue 1; 23-33

Article type:Research Article

Received:Feb 07, 2010

Accepted:Apr 10, 2010

How to Cite:Alicja Debska SlizienAnna OwczarzakDanuta KunickaEwa KrolWieslawa Lysiak SzydlowskaBoleslaw Rutkowskiet al.Erythrocyte metabolism and renal anemia in hemodialyzed patients supplemented with L-carnitine.Nephro-Urol Mon.3(1):23-33.

Abstract

Background and Aims: Potential role of L-carnitine in anemia adjuvant treatment is still a matter of concern. The aim of the study was to determine the influence of L-carnitine on renal anemia and erythrocyte metabolism in haemodialyzed (HD) patients.Methods: We studied 26 patients (13 male and 13 female) aged from 13 to 65, (mean age 38) and 30 healthy volunteers (12 male, 18 female) aged from 25 to 65, (mean age 40). HD patients showed stable hemoglobin (Hb) levels and low plasma free carnitine (FC) levels. Laboratory markers of: carnitine metabolism, hematological status, iron stores as well as erythrocyte metabolism were measured. L-carnitine (500 mg/day) was administered orally for 12 months (dose from 5.3 to 16.7 mg/kg of body weight, mean dose 9 mg/kg).

Results: After six months of oral low doses administration of L-carnitine, plasma total (TC) and FC levels increased and reached a plateau (at almost two times the initial levels) being at 12 months significantly higher than in the controls. During L-carnitine treatment a significant increase of mean Hb concentration was observed. Patients who responded (14/26) to L-carnitine differed from those who did not respond, with significantly longer dialysis time and lower both initial FC concentrations and FC/TC ratio. The following changes in erythrocyte metabolism were noticed: 1) glycolytic enzymes: significant increase of erythrocyte sodium, potassium ATPase, hexokinase and lactate dehydrogenase activities, 2) glycolytic intermediates: increase of 2,3-diphosphoglycerate and decrease of adenosine triphosphate concentrations, 3) decrease of the glucose uptake and lactate production by erythrocytes.

Conclusions: 1. L-carnitine may ameliorate anemia in some hemodialysis patients. 2. L-carnitine induces metabolic changes in erythrocytes. 3. Long-term maintenance hemodialysis patients may benefit most from L-carnitine supplementation. 4. Low doses of L-carnitine are effective in restoring the plasma carnitine pool.

Keywords

L-carnitine

Anemia

Hemodialysis

Full Text

Full text is available in PDF

comments